Treatment of Keratoconus With Advanced CXL-II

• Status: Unknown status
• Trial end date: 2019-10-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether individualized, topography-based corneal crosslinking for keratoconus can improve the optical outcomes of the treatment.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Umeå University
• Treatments: Anesthetics; Riboflavin

Criteria

Inclusion Criteria:

1. Patients planned for corneal crosslinking.

2. Uni-or bilateral keratoconus diagnosis based on the Amsler-Krumeich grading and the "Total Deviation" keratoconus quantification value from the "Belin-Ambrosio enhanced ectasia" measurements of the Pentacam HR® Scheimpflug camera, and an altered red reflex and/or an irregular cornea seen as distortion of the keratometric mires.

3. Progression of the keratoconus in the eye in question, documented with Scheimpflug photography using the Oculus Pentacam HR® Scheimpflug camera and/or repeated subjective refraction and keratometry.

4. Minimum corneal thickness of 400 μm at the thinnest point after epithelial removal.

5. ≥12 years of age

6. No ocular abnormalities except keratoconus

7. No previous ocular surgery

8. No cognitive insufficiency interfering with the informed consent.

Exclusion Criteria:

1. Age under 12

2. Any corneal abnormalities except keratoconus

3. Previous ocular surgery

4. Cognitive insufficiency